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Abstract: Cervical cancer, a potentially preventable disease, remains the second most common malignancy in women 
worldwide. Human papillomavirus (HPV) is the single most important etiological agent in cervical cancer, contributing to 
neoplastic progression through the action of viral oncoproteins, mainly E6 and E7. Cervical screening programs using Pap 
smear testing have dramatically improved cervical cancer incidence and reduced deaths, but cervical cancer still remains a 
global health burden. The biomarker discovery for accurate detection and diagnosis of cervical carcinoma and its malignant 
precursors (collectively referred to as high-grade cervical disease) represents one of the current challenges in clinical 
medicine and cytopathology.
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Introduction
Worldwide, cervical cancer is the second most common cancer in women; and is estimated to cause 
over 470,000 new cases and 233,000 deaths each year. Based on strong epidemiological evidence, 
supported by basic experimental ﬁ  ndings, there is no doubt that persistent infections with high-risk 
types of human papillomavirus (HPV) represent a necessary cause of cervical cancer (Walboomers 
et al. 1999). HPVs infect epithelial cells and cause a variety of lesions ranging from common warts to 
cervical neoplasia and cancer. Over 100 different HPV types have been identiﬁ  ed so far, with a subset 
of these being classiﬁ  ed as high risk. High-risk HPV DNA is found in almost all cervical cancers 
(>99.7%), with HPV16 being the most prevalent type in both low-grade disease and cervical neoplasia. 
Productive infection by high-risk HPV types is manifest as cervical ﬂ  at warts or condyloma that shed 
infectious virions from their surface. Viral genomes are maintained as episomes in the basal layer, with 
viral gene expression being tightly controlled as the infected cells move towards the epithelial surface. 
The pattern of viral gene expression in low-grade cervical lesions resembles that seen in productive 
warts caused by other HPV types. High-grade neoplasia represents an abortive infection in which viral 
gene expression becomes deregulated, and the normal life cycle of the virus cannot be completed. Most 
cervical cancers arise within the cervical transformation zone at the squamous/columnar junction, and 
it has been suggested that this is a site where productive infection may be inefﬁ  ciently supported 
(Doorbar, 2006). 
Although HPV infection is widespread, few people even know they are infected as the symptoms 
are seldom noticeable. It is even less well known is that nearly all cervical cancers (99.7%) are directly 
linked to previous infection with one or more of the oncogenic types of HPV (Walboomers et al. 1999). 
It is estimated that for every 1 million women infected, a hundred thousand (about 10%) will develop 
precancerous changes in their cervical tissue. Of these, about 8% of them will develop early carcinoma 
limited to cervical epithelium (carcinoma in situ; CIS) and a few of them will develop invasive cancer 
unless the precancerous lesions are detected and treated with such cases having been found to carry the 
oncogenic HPVs (e.g. types 16 and 18) that cause cervical cancer. 
 The HPV genome consists of 8 kb, and is a double-stranded DNA molecule. The relative arrange-
ment of the 8–10 open reading frames (ORFs) within the genome is the same in all papillomavirus 
types, and a particular characteristic of papilloma viruses is that the partly overlapping ORFs are arranged 
on only one DNA strand. The genome can be divided into three regions: the long control region (LCR) 
without coding potential; the region of early proteins (E1–E8); and the region of late proteins (L1 and L2) 
(Walter and Philip, 2004). E6 and E7 are the most important oncogenic proteins. These proteins have 
pleiotropic functions, such as transmembrane signaling, regulation of the cell cycle, transformation of 
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established cell lines, immortalization of primary 
cell line and regulation of chromosomal stability. 
Both E6 and E7 proteins can bind to multiple 
cellular targets. The interactions that are thought 
to be most relevant for their transforming functions 
are E6 binding, via the cellular protein E6-AP, to 
the tumor suppressor gene product p53, and E7 
binding to the retinoblastoma tumor suppressor 
gene product pRb and its related pocket proteins, 
p107 and p130 (Dyson et al. 1989; Davies, 1993). 
The ﬁ  rst interaction results in rapid ubiquitin-
dependent proteolytic degradation of p53, which 
prevents cells from undergoing p53-mediated 
apoptosis (Thomas, 1999). A consequence of E7-
pRb interaction is interfering with cell cycle 
control. In combination, the E6-p53 and E7-pRb 
interactions seem to compromise the accuracy of 
mitosis. In addition, HPV E6 can activate the telo-
mere lengthening enzyme telomerase independent 
of p53 binding, and E7 can induce abnormal 
centrosome duplication through a mechanism 
independent of inactivation of pRb and its family 
member. It is likely that these latter properties also 
contribute to the transforming characteristic of 
these viral oncoproteins.
HPV infection causes changes in expression of 
host cervical cell cycle regulatory proteins. Such 
differentially expressed host proteins and nucleic 
acids may have a role as ‘biomarker’ of dysplastic 
cells. Investigation of potential biomarkers may also 
help to unravel new pathways involved in the HPV-
mediated pathogenesis of cervical dyskaryosis.
Cervical Cancer Screening
For more than 50 years the Pap smear has been the 
mainstay of cervical screening resulting in a 
dramatic decrease in death from cervical cancer. 
However, the Pap smear has certain disadvantages 
(Table 1). It has a low sensitivity and high false 
negative rate. The data reveals that some of the 
false negative Pap smears rarely contain any 
abnormal cells on the slide (DeMay, 1996; Spitzer, 
2002). So far, an effort to seek an explanation for 
this matter has been focused on either the incom-
plete transfer of cells from collection devices to 
the slide or inadequate sampling. This results in 
the development of liquid-based cytology tech-
nique (DeMay, 1996; McGoogan et al. 1998). 
Additionally, one of the emerging explanations is 
the lack of exfoliation of dysplastic cell (shedder 
and nonshedder hypothesis) (Felix et al. 2002; 
Felix, 2003). Data from some studies have been 
shown to the effect that there is an abnormal 
expression of the adhesion molecules in a subset 
of dysplastic lesions of the cervix (et al. 2002; 
Felix, 2003). It can prevent detection by any test 
requiring exfoliated abnormal cell, including 
liquid-based technique. Despite the nonshedding 
behavior, those lesions can be identiﬁ  ed by visual 
test (Felix, 2003). There have been a number of 
visual tests which investigated for primary 
screening or used as adjunctive test of cytology 
method. These tests include cervicography, visual 
inspection with acetic acid (VIA), speculoscopy. 
At the present time, cervicography has a limited 
role as a primary screening or an adjunct to Pap 
smear (Schneider et al. 1999; Autier et al. 1999; 
Costa et al. 2000). However, as a triaging strategy 
for patients with ASCUS Pap smear, it is still a 
promising technique (Ferris et al. 2001; Brotzman, 
2002). Direct inspection is the other method based 
on applying acetic acid to the cervix and then 
visualizing it. It can be done under incandescent 
light with or without magniﬁ  cation or the chemi-
luminescent light (Wright et al. 2002; Parham, 
2003). This chemiluminescent light is of low inten-
sity. It is diffuse and produces minimal reﬂ  ective 
glare from normal tissue. There are studies showing 
that the use of chemiluminescent light allows the 
examiner to identify acetowhitening better than the 
incandescent light does (Lonky and Edwards, 
1992; Mann et al. 1993; Lonky, 2002; Parham, 
2003). Speculoscopy is developed for cervical 
screening by using chemiluminescence and low-
power magniﬁ  cation to examine the cervix after 
applying an acetic acid. It can detect acetowhite 
dysplastic lesions and has been reported to be 
effective in detecting cervical intraepithelial 
lesions when combined with the Pap smear (Lonky, 
2002; Wright et al. 2002; Parham, 2003).
Table 1. The single Pap smear test has limited sensitiv-
ity and speciﬁ  city.
Limitations of Pap smear screening
• For a high grade lesion, the sensitivity of a single 
pap smear is only 60–80%
• Errors in sampling, slide preparation and interpreta-
tion are inherent in cytology
• Sampling for atypical glandular cells is exceptionally 
difﬁ  cult
• False-positive rates range from 15–50%
• False-negative rates may reach 30%
Biomarker Insights 2006:1217
Biomarkers in Cervical Cancer
Presently, new technologies such as liquid-
based cytology, HPV DNA test have been intro-
duced. This test is used to detect the HPVs, which 
is considered the primary cause of virtually all 
cervical cancers. There are at least 30 different 
types of HPV strains that target the genital area, 
and are transmitted through sexual, skin-to-skin 
contact. Of these, approximately 13 are considered 
to be ‘high risk’ because they can trigger the devel-
opment of abnormal cells associated with cervical 
cancer. The remaining ‘low-risk’ types can cause 
genital warts. Although the Pap smear can pick up 
the cellular changes caused by high-risk types of 
HPV, it’s not as sensitive as the HPV test, which 
speciﬁ  cally detects the viral DNA. The HPV test 
is not yet routinely used by the majority of doctors, 
in part because it is more expensive than a regular 
Pap test. Therefore, it would be important to 
improve the cost-effectiveness of screening and 
reduce the psychologic burden of benign positive 
test results.
Molecular Biomarkers 
in Cervical Cancer
HPV E6 
The E6 oncoproteins of high risk HPV interfere 
with the function of the cellular tumor suppressor 
protein p53 through the induction of increased 
proteasome-dependent p53 degradation. High risk 
HPV E6 proteins target the cellular E3 ubiquitin 
ligase E6-AP to p53, resulting in the transfer of 
ubiquitin peptides from E6-AP to p53, which marks 
p53 for degradation by the 26S proteasome. Low 
risk and cutaneous epithelia-infecting HPV E6 
proteins are unable to target the cellular p53 protein 
for degradation through the proteasome pathway. 
Although E6-induced loss of p53 is an important 
element of E6-induced cellular transformation, 
recent studies have identiﬁ  ed a number of addi-
tional cellular targets of E6 that may also play an 
important role. These included the following (Filip-
pova et al. 2004; Yim et al. 2004): proteins involved 
in the regulation of transcription and DNA replica-
tion, such as p300/CBP (Huang and McCance, 
2002), Gps2 (Degenhardt and Silverstein, 2001), 
IRF-3 (Ronco et al. 1998), hMcm7 (Kukimoto 
et al. 1998), E6TP1 (Gao et al. 1999) and ADA3 
(Kumar et al. 1999); proteins, involved in apoptosis 
and immune evasion, such as Bak (Thomas and 
Banks, 1998), Bax (Bemard et al. 2003), TNF 
receptor 1 (TNF R1), FADD (Filippova et al. 2002) 
and c-Myc (Chen and Defendi, 1992); proteins 
involved with epithelial organization and differen-
tiation, such as paxillin (Tong and Howley, 1997), 
E6BP/ERC-55 (Chen et al. 1995), zyxin (Degen-
hardt and Silverstein, 2001) and ﬁ  bulin-1 (Du 
et al. 2002); proteins involved in cell-cell adhesion, 
polarity and proliferation control, which contain a 
PDZ-binding motif, such as hDLG (Kiyono et al. 
1997), hScrib (Nakagawa and Huibregtse, 2000), 
PKN (Gao et al. 2000), MAGI-1 (Glaunsinger et al. 
2000), MAGI-2, MAGI-3 (Thomas et al. 2002) or 
MUPP1 (Lee et al. 2000); and proteins involved 
in DNA repair, such as XRCC1 (Iftner et al. 2002) 
and 6-O-methylguanine-DNA methyltransferase 
(MGMT) (Strivenugopal and Ali-Osman, 2002) 
(Figure 1).
HPV E7 
HPV E7 proteins interact with the so-called ‘pRb-
associated pocket proteins,’ including the retino-
blastoma protein pRb, which are negative cell cycle 
regulators involved in the G1/S and G2/M transi-
tions. The interaction between high-risk E7 and 
pRb results in enhanced phosphorylation and degra-
dation. pRb destruction leads to the release of E2F 
family of transcription factors and the subsequent 
activation of genes promoting cell proliferation. 
However, the stimulatory effect of E7 upon cell 
proliferation not only depends on its association 
with pRb, since E7 targets the function of a 
plethora of cell cycle regulators, including cyclin 
A (Dyson et al. 1992), E (McIntyre et al. 1996) 
and cyclin-dependent kinase inhibitor p21
Cip1 
(Jones et al. 1997) and p27
kip1 (Zerfass-Thome 
et al. 1996) together with the metabolic regulators, 
acid-α-glucosidase (Zwerschke et al. 2000) and 
M2 pyruvate kinase (Zwerschke et al. 1999). HPV 
E7 also interferes with the activity of a variety of 
cellular transcription factors, such as AP-1 (Anti-
nore et al. 1996), p48 (Bamard and McMillan, 
1999), interferon regulatory factor-1 (IRF-1) (Part 
et al. 2000), forkhead transcription factor MPP2 
(Luscher-Firzlaff et al. 1999), TATA- box binding 
protein (TBP) and TATA-box binding protein- 
associated factor (TAF110) (Mazzarelli et al. 
1995), as well as with the Mi2 histone deacetylase 
(Brehm et al. 1999). Also, E7 interacts with the 
S4 subunit of the 26S proteasome (Duensing and 
Munger, 2003), a human homolog of the 
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Drosophila tumor suppressor protein Tid56 (hTid-1) 
(Schilling et al. 1998), interferon regulatory 
factor-9 (IRF-9) (Antonsson et al. 2006), Smad 
protein (Habig et al. 2006), insulin-like growth 
factor binding protein (IGFBP-3) (Mannhardt 
et al. 2000) and histone H1 kinase (Davies et al. 
1993) (Figure 2).
Mini chromosome maintenance (MCM)
DNA replication occurs only once in a single 
normal cell cycle, due to a mechanism known as 
‘licensing’ of DNA replication. This process 
requires the assembly of a protein complex which 
includes the mini chromosome maintenance 
(MCM) proteins and the cell division cycle protein 
6 (CDC6) (Cook et al. 2002; Shin et al. 2003). 
Disassembly of this complex prevents repetitive 
replication during the same cell cycle (Lei and Tye, 
2001). Changes in the expression pattern of DNA 
‘licensing’ proteins are frequently observed in 
dysplastic cells. In comparison with be present only 
during the cell cycle in normal cells, MCM proteins 
and CDC6 have been demonstrated to be overex-
pressed in dysplastic cells.
 In normal cervical epithelium, MCM protein 
staining is limited to the basal proliferating layer 
and is absent in differentiated and quiescent cells. 
In cervical glandular and squamous dysplasia, 
however, MCM expression is dramatically 
increased, suggesting its potential as a biomarker 
of cervical dysplasia (Ohta et al. 2001; Stoeber 
et al. 2002; Going et al. 2002; Alison et al. 2002; 
Davies et al. 2002; Davidson et al. 2003). MCM5 
has been the focus of much of this research, but 
MCM7 is also a highly informative marker of 
cervical cancer. The number of nuclei positive for 
MCM5 at the surface of dysplastic epithelium 
correlates with the severity of dysplasia (Williams 
et al. 1998; Freeman et al. 1999) (Table 2).
Cell division cycle protein 6 (CDC6)
Both MCM5 and CDC6 play essential roles in the 
regulation of eukaryotic DNA replication. CDC6 
was ﬁ  rst identiﬁ  ed in 1998 as a marker of cervical 
dysplastic cells in cervical biopsies and in smears 
using polyclonal antibodies. Not only MCM5 but 
also CDC6 protein expression are present in prolif-
erating cells and absent in differentiated or quies-
cent cells. In normal cervical epithelium, CDC6 
staining is absent or limited to the basal prolifera-
tive layer. However, CDC6 protein expression is 
dramatically up-regulated in squamous and glan-
dular cervical carcinomas. Several studies have 
illustrated a linear increase in CDC6 expression 
observed in normal cervix, preinvasive neoplasia 
and invasive cervical carcinoma. CDC6 was pref-
erentially expressed in areas exhibiting histological 
HPV changes. Interestingly, the expression pattern 
of CDC6 closely mirrors that of the high-risk HPV 
E6 oncoprotein, which is mainly expressed in higher 
grade lesions and invasive carcinomas (Table 3).
p16
INK4A
p16
INK4A is a tumor supressor gene and a key regu-
lator of the cell cycle. The expression pattern of 
p16
INK4A in dysplastic squamous and glandular 
cervical cells in tissue sections and in cervical smears 
has been extensively investigated (Sano et al. 1998; 
Klaes et al. 2001; Bibbo et al. 2002). In all normal 
cervical tissues examined, no p16
INK4A staining is 
evident. Additionally, all normal regions adjacent 
to cervical intraepithelial neoplasia (CIN) lesions 
do not show any detectable expression of 
p16
INK4A. While p16
INK4A identiﬁ  ed dysplastic 
squamous and glandular lesions with a sensitivity 
rate of 99.9% and a speciﬁ  city rate of 100% in 
Table 2. MCM5 and HPV oncoprotein expression.
MCM5 
• MCM5 overexpression may be due to the release of 
Rb inhibition on transcription factor E2F due to bind-
ing of HPV E7 oncoproteins
• E2F may bind to the MCM5 promoter to increase 
transcription of MCM5
• MCM5 mRNA expression increase signiﬁ  cantly with 
increasing severity of dysplasia
Table 3. CDC6 and HPV oncoprotein expression.
CDC6 
• Inactivation of Rb by HPV E7
  - Release inhibitor of E2F
  - May transcriptionally up-regulate CDC6
• CDC6 mRNA expression is signiﬁ  cantly increased 
in high-grade dysplastic cells
• Overexpressionof CDC6 promotes re-replication, 
genomic instability and DNA damage in human 
cancer cells with inactive p53, but not in cells with 
functional p53
• High-risk HPV E6 oncoprotein targets p53 for 
proteolytic degradation, allowing re-replication to 
occur in the presence of CDC6 overpression
Biomarker Insights 2006:1220
Yim and Park
F
i
g
u
r
e
 
2
.
 
C
e
l
l
u
l
a
r
 
b
i
n
d
i
n
g
 
p
a
r
t
n
e
r
s
 
f
o
r
 
H
P
V
 
E
7
.
Biomarker Insights 2006:1221
Biomarkers in Cervical Cancer
cervical biopsy sections, only a few studies have 
examined the possible prognostic value of p16
INK4A 
in cervical lesions (Murphy et al. 2003). It is now 
widely accepted that p16
INK4A is a sensitive and 
specific marker of squamous and glandular 
dysplastic cells of the cervix and also a surrogate 
marker of high risk human papillomavirus, 
suggesting a valuable adjunctive test in cervical 
cancer screening (Table 4).
Squamous cell carcinoma 
antigen (SCC)
SCC belongs to the family of serine and cysteine 
protease inhibitors (Suminami et al. 1991). This 
antigen is present in normal cervix epithelium with 
an increased expression in proportion to dyspalstic 
lesion and cervical squamous cell carcinoma. 
Though SCC is not sufﬁ  cient for use in screening, 
pretreatment serum SCC values works as an inde-
pendent prognostic factor. Approximately 60% of 
patients with cervical cancer are detected with 
elevated levels of serum SCC at initial diagnosis, 
when all stages are included (Farghaly, 1992). 
Besides, serum SSC -> SCC levels correlate 
signiﬁ  cantly with tumor stage (Crombach et al. 
1989; Duk et al. 1990). More speciﬁ  cally -> If split 
with stage, serum SCC is elevated in 24–53% of 
patients with Stage IB or IIA squamous cell 
cervical cancer, and in 75–90% of patients with 
advanced stage (FIGO IIB and higher) disease 
(Gaarenstroom et al. 1995; Duk et al. 1996). 
Several studies have concluded that serum SCC is 
useful in monitoring the course of squamous cell 
cervical cancer following primary therapy (Bolli 
et al. 1994; Bonfrer et al. 1997). Persistently 
elevated and/or increasing serum SCC levels after 
and/or during treatment suggest tumor persistence 
or progressive disease (Brioschi et al. 1991). 
Patients with plateau SCC level revealed higher 
incidence of treatment failure after radiotherapy, 
indicating SCC levels provide useful information 
for the need of further work-up and management 
(Hong et al. 1998). In view of a strong correlation 
with the clinical course, SCC is suitable for moni-
toring the early detection of recurrent or progres-
sive disease after primary treatment, and may 
therefore be useful in the management of patients. 
However, there is as yet no evidence that earlier 
detection of recurrent disease inﬂ  uences treatment 
outcome (Table 5).
Cell proliferation markers
The rate of cell proliferation in a tumor is gener-
ally thought to be of prognostic importance, and 
until recently the only means available to the 
pathologist to assess this was to count the number 
of mitotic ﬁ  gures, a technique fraught with difﬁ  -
culties and pitfalls. A number of antigens have 
now been described, which are expressed speciﬁ  -
cally by proliferating cells and which, with the use 
of monoclonal antibodies, can be demonstrated 
immunocytochemically: demonstration of these 
antigens affords, in theory at least, a much more 
accurate estimate of the number of proliferating 
cells than does a mitotic count. The two prolif-
eration antigens which have been most widely 
studied are proliferating cell nuclear antigen 
(PCNA), which is expressed during the G1 and 
early S phases of the proliferative cycle, and Ki-
67, which is expressed during the G2 and mitotic 
phases of the cycle. Ki-67 is the more reliable 
indicator of the growth fraction of a tumor, largely 
because PCNA has a long half-life and may still 
be demonstrable in post-mitotic cells (Scott et al. 
1991). The study of Ki-67 was originally, however, 
limited by the necessity to use fresh or snap frozen 
tissue (Hall and Levison, 1990), but the recently 
introduced antibody MIB-1 can be used to detect 
the antigen in fixed paraffin-embedded tissue 
(McCormick et al. 1993). The number of cell 
nuclei staining positively for these markers of 
proliferation can be estimated by simple counting 
or can be measured in an image analysis system. 
In cervical intraepithelial neoplasia both PCNA 
and Ki-67 expressions are, as compared to normal 
cervices, increased in the upper levels of the cervical 
epithelium (Konishi et al. 1991; Shurbaji et al. 1993; 
Mittal et al. 1993; Raju, 1994; McLuggage et al. 
1996), and it is thought that this staining pattern, 
particularly that for Ki-67, may be of considerable 
value in distinguishing CIN from non-neoplastic 
Table 4. p16
INK4A and HPV oncoprotein expression.
p16
INK4A 
• Inactivation of Rb by HPV E7 protein may 
up-regulate p16
INK4A
• p16
INK4A may be directly induced by the transcription 
factor E2F released from pRb after binding of HPV 
E7
• An HPV-independent pathway for p16
INK4A 
up-regulation many also exist
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lesions that may mimic CIN. Two studies of 
PCNA expression in cervical carcinoma have 
yielded conﬂ  icting results, one ﬁ  nding the PCNA 
index to be of considerable import (Oka et al. 
1992) and another being unable to show that this 
index is of any prognostic value (Al-Nafussi 
et al. 1993). Investigations of Ki-67 expression 
in cervical carcinoma have generally failed to 
show any relationship between the number of 
positively stained cells and prognosis (Cole et al. 
1992; Levine et al. 1995; Oka and Arai, 1996), 
though in one study the Ki-67 index was signiﬁ  -
cantly related to tumor size, lymphatic spread, 
and disease-free interval in patients with stage I 
disease (Garzetti et al. 1995). In endometrial 
adenocarcinomas the PCNA index has been found 
to correlate with tumor grade, depth of myome-
trial invasion, and recurrence risk (Garzetti et al. 
1996a), and it has been suggested that PCNA 
staining can be used as a method of pre-operative 
identiﬁ  cation of high risk patients (Garzetti et al. 
1996b). Ki-67expression in endometrial carci-
nomas was found to be correlated with grade but 
not with stage or depth of myometrial invasion 
in one study (Nielsen et al. 1994), but it emerged 
as a highly signiﬁ  cant indicator of tumor recurrence 
in another (Geislet et al. 1996) (Table 6). By 
contrast, others have found neither staining for 
PCNA nor Ki-67 to be of any prognostic value in 
endometrial neoplasm (Hamel et al. 1996; Nord-
strom et al. 1996).
Although few new markers have reached the 
clinic in recent years, several reported cancer 
biomarkers have been found to have low sensitivity 
in that they are found only in a small subset of 
patients with a particular type of cancer.
Needs of Biomarker Discovery
The future of clinical cancer management belongs 
to the prognostic and predictive biomarkers of 
cancer. These markers are of utmost importance as 
they will be the used to make clinical decisions 
that will eventually save lives. In the future, 
biomarkers will guide decision making during 
cancer management. Biomarkers that correctly 
predict outcome in a speciﬁ  c disease and allow 
physicians and patients to make informed treatment 
decisions need to be developed. Biomarkers will 
not only help screen, detect, diagnose, help in 
prognostic evaluation, monitor treatment and 
predict recurrence, but also play a major role in 
clinical decision making.
New Biomarker Development
Concern remains as to whether the tools available 
are well suited to provide the technological support 
to meet the demands of new biomarker develop-
ment. Until recently, the discovery of cancer 
biomarkers has been a slow approach to identify 
proteins that are dysregulated as a consequence of 
the disease and shed into the body ﬂ  uids such as 
serum, urine or saliva. Unfortunately, this approach 
is arduous and prolonged as each candidate markers 
must be identiﬁ  ed among thousands of proteins. 
The recent advancements in genomic and proteomic 
technologies including gene array technology, 
serial analysis of gene expression (SAGE) 
improved 2-DE and new mass spectrometric tech-
niques coupled with advancements in bioinfor-
matic tools, shows great promise of meeting the 
demand for the discovery of a variety of new 
biomarkers that are both sensitive and speciﬁ  c 
Table 6. Cell proliferation markers PCNA and Ki-67.
 Type  Limitation
PCNA  Proliferation marker  Multiple factors affect staining intensity
Ki-67  Proliferation marker  Multiple factors affect expression levels
Table 5. Currently available and potentially useful serum marker squamous cell carcinoma (SCC).
Squamous cell carcinoma (SCC) 
• Pre-treatment identiﬁ  cation of high risk group with lymph node metastases in squamous cell cervical cancer
• Pre-treatment prediction of prognosis in squamous cell cervical cancer
• Prediction of response to treatment in squamous cell cervical cancer
• Monitoring disease and detecting recurrent disease in squamous cell cervical cancer
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(Chatterjee and Zetter, 2005). Like these, high-
throughput approaches are useful in cancer 
biomarker discovery and clinical diagnostics. The 
combined use of proteomics, genomics and bioin-
formatics tools may hold promise for early detec-
tion of disease by proteomic patterns, diagnosis 
based on proteomic signatures as a complement to 
histopathology, individualized selection of thera-
peutic combinations that best target the entire 
disease-speciﬁ  c protein network, rational modula-
tion of therapy based on changes in the diseased 
protein network associated with drug resistance 
and understanding of carcinogenesis. 
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